Cytoart/BioSwan is the only company worldwide with granted patents in both the United States and China specifically covering anti-idiotype antibodies for CAR-T detection.
For our partners, this intellectual property portfolio provides access to differentiated and protected CAR detection technologies, supported by:
* Reagents matched to specific CAR constructs
* Custom anti-idiotype antibody development
* Flow cytometry assay development and optimization
* Support from early research through manufacturing QC and clinical monitoring
* Scalable supply and long-term product support
* Opportunities for co-development and strategic collaboration
Our goal is not simply to provide an antibody, but to help cell therapy developers establish reliable CAR detection strategies throughout the product lifecycle.
We welcome partnerships with biotechnology companies, academic centers, hospitals, CDMOs, instrument manufacturers, and cell therapy platform providers.
#CART #CellTherapy #FlowCytometry #AntiIdiotypeAntibody #Biotechnology #Patent #Innovation #Partnership #Cytoart #BioSwan